Central Pacific Bank Trust Division lifted its holdings in shares of Boston Scientific Co. (NYSE:BSX – Free Report) by 10.6% during the 3rd quarter, Holdings Channel.com reports. The firm owned 27,883 shares of the medical equipment provider’s stock after buying an additional 2,677 shares during the quarter. Central Pacific Bank Trust Division’s holdings in Boston Scientific were worth $2,337,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Mattson Financial Services LLC purchased a new stake in Boston Scientific during the 2nd quarter valued at $2,339,000. Newbridge Financial Services Group Inc. lifted its position in shares of Boston Scientific by 2,100.5% in the 2nd quarter. Newbridge Financial Services Group Inc. now owns 9,132 shares of the medical equipment provider’s stock worth $703,000 after purchasing an additional 8,717 shares during the period. Sanctuary Advisors LLC purchased a new stake in shares of Boston Scientific in the 2nd quarter worth about $5,349,000. Brown Financial Advisors purchased a new stake in shares of Boston Scientific in the 2nd quarter worth about $1,423,000. Finally, RiverFront Investment Group LLC bought a new position in shares of Boston Scientific in the 2nd quarter worth about $222,000. Institutional investors own 89.07% of the company’s stock.
Boston Scientific Stock Performance
BSX opened at $84.47 on Thursday. The company has a current ratio of 1.61, a quick ratio of 1.14 and a debt-to-equity ratio of 0.44. The company has a market cap of $123.93 billion, a price-to-earnings ratio of 70.98, a PEG ratio of 2.78 and a beta of 0.79. The company’s 50 day moving average is $79.69 and its 200 day moving average is $75.62. Boston Scientific Co. has a 12-month low of $48.35 and a 12-month high of $84.89.
Insider Buying and Selling
In related news, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $81.70, for a total value of $570,511.10. Following the sale, the executive vice president now owns 37,468 shares in the company, valued at $3,061,135.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Over the last 90 days, insiders have sold 20,949 shares of company stock worth $1,673,685. Insiders own 0.50% of the company’s stock.
Analyst Ratings Changes
Several research analysts recently issued reports on BSX shares. Deutsche Bank Aktiengesellschaft increased their price target on shares of Boston Scientific from $73.00 to $78.00 and gave the stock a “hold” rating in a research note on Thursday, July 25th. Evercore ISI increased their price target on shares of Boston Scientific from $82.00 to $90.00 and gave the stock an “outperform” rating in a research note on Tuesday. Canaccord Genuity Group increased their price target on shares of Boston Scientific from $83.00 to $88.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. JPMorgan Chase & Co. increased their price target on shares of Boston Scientific from $82.00 to $85.00 and gave the stock an “overweight” rating in a research note on Thursday, July 25th. Finally, TD Cowen raised their price objective on shares of Boston Scientific from $77.00 to $86.00 and gave the company a “buy” rating in a research note on Tuesday, July 16th. Three investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $87.10.
Check Out Our Latest Report on BSX
Boston Scientific Profile
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.
Read More
- Five stocks we like better than Boston Scientific
- How to Use the MarketBeat Excel Dividend Calculator
- SCHD ETF: Unlocking Passive Income With Strong Returns
- What is a Dividend King?
- NuScale Power Soars 270% – Analysts Forecasts More Gains Ahead
- Health Care Stocks Explained: Why You Might Want to Invest
- Harness the Power of Dividend ETFs for Steady Income Growth
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX – Free Report).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.